Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anlotinib hydrochloride plus docetaxel versus docetaxel alone for the treatment of advanced non-squamous non-small-cell lung cancer after system chemotherapy: a multicentre randomised controlld clinical trial

Trial Profile

Anlotinib hydrochloride plus docetaxel versus docetaxel alone for the treatment of advanced non-squamous non-small-cell lung cancer after system chemotherapy: a multicentre randomised controlld clinical trial

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs Anlotinib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top